Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rami Komrokji

Showing results (81-90 of 129) with videos related to

Pageof 13
Sort By:
Blood Advances|May 5, 2023
Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national studyGregory A Abel, Donnie Hebert, Cecilia Lee, et al.
Blood Advances|January 3, 2024
Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AMLOnyee Chan, Najla Al Ali, Hammad Tashkandi, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 20, 2024
Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysisJulio C Chavez, Ariel Grajales, Jose Sandoval-Sus, et al.
Leukemia & Lymphoma|August 27, 2021
Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosisRami Komrokji, Megan Melody, Najla Al Ali, et al.
The Lancet. Haematology|March 29, 2023
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion studyGuillermo Garcia-Manero, Aaron D Goldberg, Eric S Winer, et al.
Blood Advances|May 31, 2024
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosisAaron T Gerds, Claire Harrison, Jean-Jacques Kiladjian, et al.
Leukemia Research|February 12, 2025
Characteristics and survival outcomes of patients with myelodysplastic syndromes with isolated 11q deletionKensuke Takaoka, Rami Komrokji, Kelly Chien, et al.
Transfusion|November 24, 2016
Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United StatesAlexander B Pine, Eun-Ju Lee, Mikkael Sekeres, et al.
BMC Cancer|August 20, 2016
Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort studyDavid P Steensma, Medrdad Abedi, Rafael Bejar, et al.
British Journal of Haematology|December 12, 2023
TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q)Ayalew Tefferi, Farah Fleti, Onyee Chan, et al.
Pageof 13

Showing results (81-90 of 129) with videos related to

Sort By:
Pageof 13
Blood Advances|May 5, 2023
Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national studyGregory A Abel, Donnie Hebert, Cecilia Lee, et al.
Blood Advances|January 3, 2024
Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AMLOnyee Chan, Najla Al Ali, Hammad Tashkandi, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 20, 2024
Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysisJulio C Chavez, Ariel Grajales, Jose Sandoval-Sus, et al.
Leukemia & Lymphoma|August 27, 2021
Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosisRami Komrokji, Megan Melody, Najla Al Ali, et al.
The Lancet. Haematology|March 29, 2023
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion studyGuillermo Garcia-Manero, Aaron D Goldberg, Eric S Winer, et al.
Blood Advances|May 31, 2024
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosisAaron T Gerds, Claire Harrison, Jean-Jacques Kiladjian, et al.
Leukemia Research|February 12, 2025
Characteristics and survival outcomes of patients with myelodysplastic syndromes with isolated 11q deletionKensuke Takaoka, Rami Komrokji, Kelly Chien, et al.
Transfusion|November 24, 2016
Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United StatesAlexander B Pine, Eun-Ju Lee, Mikkael Sekeres, et al.
BMC Cancer|August 20, 2016
Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort studyDavid P Steensma, Medrdad Abedi, Rafael Bejar, et al.
British Journal of Haematology|December 12, 2023
TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q)Ayalew Tefferi, Farah Fleti, Onyee Chan, et al.
Pageof 13